05:13 PM EDT, 06/03/2024 (MT Newswires) -- Merus (MRUS) said Monday that its MCLA-129 product candidate demonstrated a reduction in target lesion tumor size in 80% of patients with certain types of non-small-cell lung cancer who were available for evaluation after two or more treatments.

Of the 22 patients treated as of the Feb. 16 cutoff date, 15 were available for evaluation, with three of those patients experiencing confirmed partial responses and another six patients having unconfirmed partial responses. Tumors in 12 of the 15 patients reduced in size, the company said.

All patients received MCLA-129 in monotherapy at the dose of 1,500 milligrams every two weeks and a median of two lines of prior therapy, the drugmaker said.

Merus said it plans to begin a group investigating MCLA-129 in combination with chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer later in 2024.

Price: 51.75, Change: -1.19, Percent Change: -2.25